Related Experiment Video
Updated: Aug 1, 2025
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
68.8K
Lipohypertrophy and Insulin: An Old Dog That Needs New Tricks
Jingtong Huang1, Andrea M Yeung1, David Kerr1
1Diabetes Technology Society, Burlingame, California.
Summary
Insulin-associated lipohypertrophy (LH), a common complication, can be prevented and treated. Proper insulin injection techniques are key to managing this condition and its effects on glucose control.
Area of Science:
- Endocrinology
- Dermatology
- Metabolic Disorders
Background:
- Insulin-associated lipohypertrophy (LH) is a frequent dermatologic complication of insulin therapy.
- It involves the accumulation of fatty subcutaneous nodules due to repeated insulin injections in the same site.
Purpose of the Study:
- To review current practical knowledge on insulin-associated lipohypertrophy (LH).
- Emphasis on clinical aspects including pathophysiology, consequences, diagnosis, prevention, and treatment.
Main Methods:
- Comprehensive review of published literature.
- Inclusion of expert contributions focusing on clinical aspects.
Main Results:
- LH is the most common skin complication of insulin therapy.
- Risk factors include repeated injections, injection trauma, and reusing needles.
- LH can affect insulin absorption, leading to glucose variability, despite reduced injection pain. Ultrasound can detect early-stage LH.
Conclusions:
- Physiological and psychological impacts of LH are preventable and treatable.
- Education on proper insulin injection techniques is crucial for management.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
322
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
322
01:16Insulin: Dosing Regimen and Adverse Effects
219
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
219
01:24Glucagon-like Receptor Agonists
373
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
373
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
242
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
242
01:27Insulin Formulations: Types and Delivery
242
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
242
01:15Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306